Alnylam Pharmaceuticals, Inc.
ALNY
$473.29
$8.361.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 2.72B | 2.86B | 2.63B | 2.69B | 2.78B |
| Total Receivables | 964.77M | 567.11M | 418.04M | 405.31M | 353.85M |
| Inventory | 75.38M | 71.69M | 65.58M | 78.51M | 75.99M |
| Prepaid Expenses | 188.04M | 147.31M | 152.42M | 116.96M | 145.35M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 3.95B | 3.64B | 3.27B | 3.30B | 3.36B |
|
|
|||||
| Total Current Assets | 3.95B | 3.64B | 3.27B | 3.30B | 3.36B |
| Net Property, Plant & Equipment | 693.14M | 692.19M | 695.92M | 693.93M | 703.41M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 205.71M | 230.13M | 249.64M | 250.77M | 146.21M |
| Total Assets | 4.85B | 4.57B | 4.21B | 4.24B | 4.21B |
|
|
|||||
| Total Accounts Payable | 117.59M | 102.39M | 97.40M | 88.42M | 70.81M |
| Total Accrued Expenses | 1.15B | 918.97M | 704.17M | 795.16M | 946.17M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 160.45M | 143.62M | 127.80M | 154.90M | 132.66M |
| Total Finance Division Other Current Liabilities | 123.79M | 135.87M | 146.26M | 147.79M | 71.03M |
| Total Other Current Liabilities | 123.79M | 135.87M | 146.26M | 147.79M | 71.03M |
| Total Current Liabilities | 1.56B | 1.30B | 1.08B | 1.19B | 1.22B |
|
|
|||||
| Total Current Liabilities | 1.56B | 1.30B | 1.08B | 1.19B | 1.22B |
| Long-Term Debt | 2.39B | 2.37B | 2.36B | 2.36B | 2.36B |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 223.42M | 224.45M | 230.06M | 229.54M | 236.03M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 449.43M | 418.47M | 428.31M | 398.11M | 358.49M |
| Total Liabilities | 4.62B | 4.32B | 4.10B | 4.17B | 4.17B |
|
|
|||||
| Common Stock & APIC | 7.42B | 7.69B | 7.50B | 7.39B | 7.26B |
| Retained Earnings | -7.16B | -7.41B | -7.35B | -7.29B | -7.20B |
| Treasury Stock & Other | -21.78M | -29.95M | -37.52M | -34.52M | -24.83M |
| Total Common Equity | 233.89M | 250.59M | 115.44M | 67.09M | 32.35M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 233.89M | 250.59M | 115.44M | 67.09M | 32.35M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 233.89M | 250.59M | 115.44M | 67.09M | 32.35M |
|
|
|||||